Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor. | J Cardiovasc Pharmacol;79(2): 161-167, 2022 02 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.

Beavers, Craig J; Effoe, Samuel Aaron; Dobesh, Paul P.

Affiliation

Beavers CJ; Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY.
Effoe SA; Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY.
Dobesh PP; Department of Pharmacy Practice and Science, Cardiovascular Services, Baptist Health Paducah, Lexington, KY; and.

J Cardiovasc Pharmacol ; 79(2): 161-167, 2022 02 01.

Article in En | MEDLINE | ID: mdl-34132688

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Acute Coronary Syndrome / Organophosphonates Limits: Humans Language: En Journal: J Cardiovasc Pharmacol Year: 2022 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Acute Coronary Syndrome / Organophosphonates Limits: Humans Language: En Journal: J Cardiovasc Pharmacol Year: 2022 Document type: Article Country of publication: